Novartis' Pelacarsen Fails to Deliver in Key Cardiovascular Trial

In a disappointing turn of events for Novartis, their experimental cardiovascular medication, pelacarsen, did not meet expectations in a crucial clinical trial. The company disclosed the results on Friday, marking a significant setback in the quest to address a prevalent risk factor for heart disease.

The drug had previously demonstrated promise in earlier studies, notably its ability to significantly decrease levels of lipoprotein(a), commonly referred to as Lp(a). Elevated Lp(a) is associated with an increased risk of serious cardiovascular issues, making pelacarsen a hopeful contender in managing heart disease.

However, the Phase 3 HORIZON trial results revealed that pelacarsen did not effectively lower the incidence of cardiovascular-related deaths or emergencies, such as heart attacks and strokes, when compared to a placebo. This outcome raises questions about the future of pelacarsen and its potential role in cardiovascular treatment.

Source: www.statnews.com